Financial Review: Pharming Group (PHGUF) versus The Competition

Pharming Group (OTCMKTS:PHGUF – Get Rating) is one of 975 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Pharming Group to similar businesses based on the strength of its earnings, analyst recommendations, institutional ownership, valuation, risk, dividends and profitability.

Institutional and Insider Ownership

41.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Pharming Group has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Pharming Group’s competitors have a beta of 0.84, indicating that their average stock price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Pharming Group and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	0	0	0	0	N/A
Pharming Group Competitors	3716	14250	40355	680	2.64

As a group, “Pharmaceutical preparations” companies have a potential upside of 109.42%. Given Pharming Group’s competitors higher possible upside, analysts plainly believe Pharming Group has less favorable growth aspects than its competitors.

Profitability

This table compares Pharming Group and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	14.90%	15.52%	7.77%
Pharming Group Competitors	-3,336.83%	-179.75%	-35.57%

Valuation & Earnings

This table compares Pharming Group and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pharming Group	$198.87 million	$16.00 million	36.26
Pharming Group Competitors	$1.83 billion	$246.79 million	-6.46

Pharming Group’s competitors have higher revenue and earnings than Pharming Group. Pharming Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

About Pharming Group

(Get Rating)

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.